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Association of traditional Chinese medicine
therapy and the risk of dementia in
patients with hypertension: a nationwide
population-based cohort study
Kuen-Hau Chen1, Ming-Hsien Yeh1,2,3, Hanoch Livneh4, Bor-Chyuan Chen1, I-Hsin Lin2, Ming-Chi Lu5,6,
Tzung-Yi Tsai7,8,9* and Chia-Chou Yeh1,2,3*
Abstract
Background: Patients with hypertension (HTN) reportedly have a higher risk of developing dementia. However,
it remains unclear if use of Traditional Chinese Medicine (TCM), the most common form of complementary and
alternative medicine, can help lower the risk of dementia for these patients. So the aim of the study was
to investigate the effects of TCM on dementia risk among patients with hypertension.
Methods: This longitudinal cohort study used the Taiwanese National Health Insurance Research Database
(NHIRD) to identify 143,382 newly diagnosed hypertension patients aged 20–90 years who received treatment
between 1998 and 2007. Among them, 52,365 (36.52%) had received TCM after the onset of hypertension
(TCM users), and the remaining 91,017 patients (63.48%) were designated as a control group (non-TCM users).
All enrollees were followed until the end of 2012 to record the incidence of dementia. A Cox proportional
hazards regression model was used to compute the hazard ratio (HR) of dementia in patients who received TCM.
Results: During the 15-year follow-up, 3933 TCM users and 10,316 non-TCM users developed dementia, representing
an incidence rate of 8.41 and 11.55%, respectively, per 1000 person-years. TCM users had a significantly reduced risk of
dementia compared to non-TCM users (adjusted HR = 0.76; 95% confidence interval [CI] = 0.74–0.81). The predominant
effect was observed among those treated with TCM longer than 180 days (adjusted HR = 0.65; 95% CI = 0.62–0.69).
Among the commonly used TCM products, Tian-Ma-Gou-Teng-Yin, Dan-Shen (Radix Salviae Miltiorrhizae), Chuan-Niu-Xi
(Radix Cyathulae), Ge-Gen (Radix Puerariae), Jia-Wei-Xiao-Yao-San, and Jue-Ming-Zi (Semen Cassiae) were significantly
associated with a lower risk of dementia.
Conclusions: Results from this population-based study support the effects of TCM on reducing dementia risk, which
may provide a reference for dementia prevention strategies.
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Background
Dementia is characterized by impairment of cognition
involving learning, memory, language, executive function,
complex attention, perceptual-motor skills, and social cog-
nition [1]. In 2015, 46.8 million people worldwide had
dementia, and 9.9 million new cases are reported every
year [2]. The occurrence and irreversibility of this illness
pose a heavy burden on society and families. The esti-
mated global costs of dementia care have increased from
$604 billion in 2010 to $818 billion in 2015 (in US dol-
lars), representing an increase of 35.4% [2]. Although
acetylcholinesterase inhibitors and N-methyl-D-aspartate
(NMDA) receptor antagonists have been effective for
enabling patients to maintain global function, there is cur-
rently no treatment to halt or reverse the degenerative
progression of dementia [3].
Nowadays, Traditional Chinese Medicine (TCM) has
become increasingly popular as an alternative treatment
for several critical illnesses, such as diabetes mellitus [4],
atopic dermatitis [5], cancer [6], fractures [7], or vertigo
[8]. Although previous research has indicated that several
TCM herbs have shown potential benefits for dementia
intervention [9], the evidence of long-term effects of TCM
on dementia risk is still limited.
Hypertension (HTN), a common chronic disorder, is a
critical challenge in global public health. It is noteworthy
that HTN has been consistently associated with an in-
creased risk of dementia in most cross-sectional and
longitudinal cohort studies, and appears to be more rele-
vant when it presents in middle age rather than later in
life [10–12]. Results of previous studies have demon-
strated that TCM can lower blood pressure and modify
vascular risk factors in patients with HTN [13, 14],
which may be related to dementia [15, 16]. However, to
our knowledge, there is a paucity of information on the
benefit of TCM for dementia risk, in particular for sub-
jects with HTN. To address this concern, we studied
claims data from the Taiwanese National Health Insur-
ance Research Database (NHIRD) to determine the ef-
fect of TCM services on subsequent risk of dementia
among HTN individuals. The results of this study may




This retrospective cohort study used Taiwan’s Longitu-
dinal Health Insurance Database (LHID), which is main-
tained by the National Health Insurance Administration
and available to Taiwanese researchers. In 1995, Taiwan
launched a single-payer national health insurance pro-
gram designed to remove financial barriers to medical
care for all legal residents. As of 2010, over 99% of
Taiwan’s population have been enrolled in this program
[17]. The LHID, a sub-dataset of the NHI program, is
made up of data from 1 million randomly sampled
Taiwanese citizens alive in 2000. We collected all med-
ical records available for these individuals from 1997 to
2012. Because a multistage stratified systematic sampling
method was used, no statistically significant differences
in sex or age existed between the 1 million insured indi-
viduals and the general population [17]. This database
contains all NHI enrollment files, claims data, and the
registry for prescription drugs, which thus provides
comprehensive pharmacological utilization information
for subjects covered by the insurance program. To date,
more than 300 published papers have utilized this de-
identified secondary data.
This study was conducted in accordance with the
Helsinki Declaration, and it was also evaluated and
approved by the local Institutional Review Board and
Ethics Committee of Buddhist Dalin Tzu Chi Hospital,
Taiwan (No. B10004021–1). Since the LHID files contain
only de-identified secondary data, the review board
waived the requirement for obtaining informed consent
from the patients.
Study population
The participant selection method is shown in Fig. 1. All
diagnoses in this insurance claims data were coded with
One million random samples from NHIRD
(n=1,000,000)
Exclusion of cases without HTN 
(n=792,264)
Cases of HTN (n=207,736)
Subjects 20-90 years of age 
(n=145,734)
New diagnosed HTN cases
from 1998-2007 (n=146,583)
Exclusion of those with dementia prior 





3,933 cases of dementia 10,316 cases of dementia
Fig. 1 A flowchart about the selection and follow-up of study subjects
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the International Classification of Disease, 9th Revision,
Clinical Modification (ICD-9-CM). With it, we identified
patients 20 to 90 years of age with newly diagnosed
HTN within the 1998–2007 time period (ICD-9-CM
codes: 401–405) as the study cohort. To reduce concern
about disease misclassification, we selected only those
cases where at least three diagnoses were made during
outpatient visits or cases where patients were admitted
to a hospital with a primary diagnosis of HTN within
the observational period (n = 145,734). Patients with
HTN who were followed for less than 3 months or who
had a prior diagnosis of dementia before the first-time
HTN diagnosis were excluded (n = 2352). Patients with
dementia were identified if they had at least two treat-
ment claims for dementia during outpatient visits or if
they had been hospitalized with dementia for ICD-9-CM
codes 290, 294, or 331. A final group of 143,382 subjects
with HTN were included in the data analysis.
In Taiwan, only certified Chinese medicine physicians
are entitled to provide TCM services. We used the fre-
quency of visits for TCM to verify the TCM exposure of
each study subject. HTN subjects who received TCM for
more than 30 days were considered TCM users, whereas
those treated for 30 days or less were considered non-
TCM users [8]. The index date of the follow-up period
for HTN subjects who were classified as non-TCM users
was assigned to the date of the first HTN diagnosis,
whereas the index date of follow-up period for HTN
cases with TCM usage was assigned to the first date of
the initiation of TCM services. The end date of the
follow-up period for both groups was assigned as the
date of the earliest of one of the following: a diagnosis of
dementia, the date of withdrawal from the insurance
program, or the date of December 31, 2012.
Demographic characteristics and comorbidity
Demographic characteristics considered in this study
included age, gender, income for estimating insurance
payment, the availability of TCM resources, and
urbanization level of the subject’s residential area. The
subjects’ monthly incomes were stratified into 3 levels: ≤
New Taiwan Dollar (NTD) 17,880, NTD 17,881–NTD
43,900, and ≥ NTD 43,901. Urbanization levels were di-
vided into 3 strata: urban (levels 1–2), suburban (levels
3–4), and rural (levels 5–7) areas. Level 1 refers to the
“most urbanized” and level 7 refers to the “least urban-
ized” communities [18]. The comorbid medical condi-
tions, for each individual, were evaluated by using the
Charlson-Deyo comorbidity index (CCI) [19]. This index
is a widely used method of categorizing comorbidities of
patients based on the ICD-9 diagnosis codes found in
administrative data. In this study, only diagnoses given
ahead of and in concurrence with the diagnosis of HTN
were regarded as underlying comorbidities.
Statistical analysis
We used the chi-square test and Student’s t-test to
examine the differences in demographic characteristics
and comorbidities between subjects who received and
those who did not receive TCM services. Thereafter, the
Cox proportional hazards regression analysis was applied
to compute the hazard ratio (HR) with 95% confidence
intervals (CI) of dementia risk in association with TCM
use. To test the robustness of the relationship between
TCM use and dementia risk, we divided the TCM users
into two subgroups: one group used TCM for 30 to
180 days, and the other group used TCM for more than
180 days. Furthermore, a stratified analysis by age and
gender using Cox proportional hazards regression was
also conducted to assess the relative risk of dementia
among the subjects who received and did not receive
TCM services. The proportional-hazards assumption
was verified using plots of log (−log (survival function)
vs log (time) and Schoenfeld residuals vs time. All ana-
lyses were conducted using SAS version 9.3 (SAS Insti-
tute Inc., Cary, NC, USA), at a P < 0.05 statistically
significant level.
Results
We identified 143,382 patients with HTN during the
period from 1998 to 2007. Of these, 52,365 subjects re-
ceived TCM services and 91,017 subjects were classified
as non-TCM users. Table 1 shows the basic characteris-
tics of the two groups. Compared to the non-TCM
users, HTN patients receiving TCM services were more
likely to be female and younger, to have lower monthly
incomes and tobacco use, to have higher CCI scores,
and to reside in an urban area (all P < 0.01).
Among the 143,382 HTN subjects, 14,249 first epi-
sodes of dementia occurred; 10,316 were reported
among the non-TCM users and 3933 among the TCM
users during the follow-up of 892,960.27 and 467,500.55
person-years (PYs), respectively. The incidence rate of
dementia was lower among TCM users than among
non-TCM users (8.41 vs 11.55, respectively, per 1000
PYs), with an adjusted HR of 0.76 (95% CI = 0.74–0.81)
(Table 2). Of note, using TCM services for more than
180 days was associated with a 35% decreased risk of
dementia among HTN patients (95% CI = 0.62–0.69).
As for the sex-specific risk of dementia, we discovered
that both female and male HTN patients receiving TCM
services had a significantly decreased risk of dementia,
with an adjusted HR of 0.71 (95% CI = 0.68–0.74) and
0.84 (95% CI = 0.81–0.91), respectively (Table 3). Add-
itionally, because a significant interaction of age and sex
in relation to TCM use occurred, we further performed
a stratified analysis by age and sex to determine the
effect of TCM on dementia risk. In general, use of TCM
was associated with a lower risk of dementia, irrespective
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of sex. The multivariable stratified analysis verified signifi-
cant associations of dementia risk with TCM use among
male subjects with HTN aged ≤50 years (adjusted
HR = 0.72; 95% CI = 0.57–0.89); for female subjects, the
more beneficial effect of TCM on the risk of dementia was
noted for those older than 50 years (adjusted HR = 0.70;
95% CI = 0.67–0.75) (Table 3).
The most commonly prescribed TCMs for patients
with HTN are summarized in Table 4. Of the 15 most
common TCMs, 6 were herbal formulas and 9 were sin-
gle herbs. Tian-Ma-Gou-Teng-Yin (TMGTY) was the
most used herbal formula, followed by Dan-Shen and
Gou-Teng-San. Of these TCMs, Tian-Ma-Gou-Teng-Yin,
Dan-Shen, Chuan-Niu-Xi, Ge-Gen, Jia-Wei-Xiao-Yao-
San, and Jue-Ming-Zi were found to be significantly
related to a lower risk of dementia (Table 5).
Discussion
To our knowledge, this is the first population-based co-
hort study to address the influence of TCM on the risk of
dementia among patients with HTN. The study results
provide more robust findings about the effects of TCM in
this patient population, and may allow clinicians to choose
the most appropriate treatment for HTN individuals.
Results of this 15-year follow-up study showed that
subjects with HTN who received TCM services exhib-
ited a 24% reduced risk of dementia as compared to
those who did not receive TCM services. In addition, the
use of TCM services for more than 180 days was associ-
ated with a 35% decreased risk of developing dementia.
Furthermore, the stratified analysis supported that the
TCM intervention significantly reduced the risk of de-
mentia in females more than for males, with adjusted
HR of 0.71 and 0.84, respectively. One contributing fac-
tor might be that Taiwanese females often exhibit better
adherence behaviors than males [20], thus preventing
their disease from worsening.
The findings of this study also showed that TCM ser-
vices may result in fewer effects on females younger than
50 years of age compared to males of similar age. We
speculate that younger women may benefit from higher
estrogen levels, which could decrease serum low-density
lipoprotein-cholesterol (LDL-C) levels and curb coronary
thrombosis and atherosclerosis by regulating vascular
smooth muscle and endothelial cells [21]. This biochem-
ical benefit may lessen the corresponding effect of TCM
services. Taken together, these results clearly demonstrate
that earlier and longer use of TCM among HTN patients
is associated with reduction of dementia risk.
The two principal types of dementia, Alzheimer’s dis-
ease (AD) and vascular dementia (VaD), account for
about 70 and 15% of cases of dementia, respectively [22].
Reducing the amount of beta-amyloid protein (Aβ) and
tau protein in the brain and modulating Aβ toxicity, in-
cluding inflammatory response, oxidative stress, and
Table 1 Demographic data and selected comorbidities of the
study subjects
Variables Non-TCM users TCM users P-value
n = 91,017 (%) n = 52,365 (%)
Age (yr) <0.001
≤50 22,971 (25.2) 16,461(31.4)
>50 68,046 (74.8) 35,904 (68.6)
Mean (SD) 59.74 (13.6) 57.19 (12.4) <0.001
Gender <0.001
Female 40,794 (44.8) 29,597(56.5)
Male 50,223(55.2) 22,768 (43.5)
Monthly income <0.001
Low 39,976(43.9) 21,506 (41.1)
Median 46,352 (50.9) 28,123 (53.7)
High 4689 (5.2) 2736 (5.2)
Residential area <0.001
Urban 49,720(54.6) 29,629 (56.6)
Suburban 14,209(15.6) 8426 (16.1)
Rural 27,088(29.8) 14,310 (27.3)
Tobacco use 0.002
Yes 352 (0.4) 150 (0.3)
No 90,665 (99.6) 52,215 (99.7)
CCI <0.001
Mean (SD) 3.50 (4.42) 4.23 (7.03)
TCM Traditional Chinese Medicine, SD, standard deviation; CCI Charlson-Deyo
comorbidity index
Table 2 Risk of dementia for HTN subjects with and without TCM
Patient group Event PYs Incidence Crude HR (95% CI) Adjusted HRa (95% CI)
Non-TCM users 10,316 892,960.27 11.55 1 1
TCM users 3933 467,500.55 8.41 0.73(0.71–0.76) 0.76 (0.74–0.81)
TCM use within
30–180 days
2706 289,829.43 9.34 0.82 (0.78–0.85) 0.86 (0.82–0.90)
TCM use for more than 180 days 1277 177,671.13 6.91 0.60 (0.57–0.64) 0.65 (0.62–0.69)
TCM Traditional Chinese Medicine, PYs per 1000 person-years, HR hazard ratio, CI confidence interval
aModel adjusted for age, gender, urbanization level, monthly income, and CCI scores
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neuronal apoptosis, have been considered the most
promising therapeutic strategies available for controlling
the progression of dementia [23, 24].
In our study, six TCMs were found to be significantly
related to a lower risk of dementia, and these have been
reported to exert most of the neuroprotective activities
mentioned above. Additionally, most of these TCMs
have shown medicinal benefits in reducing vascular risk
factors of AD and VaD, and thus they may also help re-
duce the risk of dementia [15, 16]. The possible pharma-
cological mechanisms of the most common TCMs for
the treatment of patients with HTN are summarized in
Tables 4 and 5.
We discovered that the most commonly prescribed
herbal formula, Tian-Ma-Gou-Teng-Yin (TMGTY), was
used in TCM for relieving symptoms related to high
blood pressure, such as headaches and dizziness. Results
of previous studies have shown that TMGTY has signifi-
cant effects on a variety of HTN-caused cardiovascular
diseases [14]. Recent scientific evidence has also demon-
strated that TMGTY provides neuroprotective effects
for patients with Parkinson’s disease [25]. TMGTY has
also been found to inhibit the NMDA receptor. This
leads to a reduction in necrosis and apoptosis in neur-
onal cells through a variety of pharmacological effects,
including anti-inflammatory, antioxidative, and anti-
apoptotic activities [26]. Moreover, the components of
TMGTY could decrease the activity of acetylcholinester-
ase and show potent anti-aggregation effects on Aβ
proteins [27, 28].
Dan-Shen (Radix Salviae Miltiorrhizae) and Ge-Gen
(Radix Puerariae) are two herbs frequently used for the
treatment of angina and other cardiac symptoms in
TCM. Recent studies have demonstrated their cardio-
protective and anti-atherosclerosis effects. Results of
pharmacological studies suggest that these herbs can
control high blood pressure, lower serum lipids, and im-
prove microcirculation [29]. Dan-Shen demonstrated
neuroprotective effects [29], including inhibition of Aβ ag-
gregation, oligomerization, and fibril formation through
upregulation of activity of alpha-secretases [30]. Dan-Shen
also acts as an acetylcholinesterase inhibitor [31], and it
could improve age-related oxidative stress and inflamma-
tory response [32], protect endothelial cells from hydrogen
peroxide damage, and inhibit apoptosis [33]. Ge-Gen was
found to show potential medicinal benefits in diabetes
and cardiovascular and cerebrovascular diseases [34],
and it could alleviate neurological deficits and improve
learning and memory after ischemia/reperfusion-in-
duced cerebral microcirculatory disturbances [35]. Re-
cent studies have also demonstrated that Ge-Gen could
inhibit Aβ plaque accumulation [36], suppress tau pro-
tein expression [37], and antagonize neuronal apoptosis
induced by oxidative stress [38].
Chuan-Niu-Xi (Radix Cyathulae) has demonstrated
various beneficial pharmacological activities, including an-
algesic, immunostimulant, antitumor, anti-inflammatory,
and antiaging effects. Its use removes blood stasis, restores
menstrual flow, and induces diuresis for treating stran-
guria. It also has antioxidant qualities [39].
Jia-Wei-Xiao-Yao-San is widely used to relieve emotional
and neuropsychological disorders such as depression, stress
[40], and dyskinesia in patients with schizophrenia [41].
Researchers have also shown that Jia-Wei-Xiao-Yao-San
can reduce tremors of antipsychotic-induced parkinsonism
[42], relieve migraine headache [43], and improve the
Table 3 Incidence and dementia risk for HTN patients with and without TCM in the stratification of sex and age
Variables Non-TCM users TCM users Crude HR
(95% CI)
Adjusted HR
(95% CI)Case PYs Incidence Case PYs Incidence
Female

























TCM Traditional Chinese Medicine, PYs person-years, HR hazard ratio, CI confidence interval
aModel adjusted for urbanization level, monthly income, and CCI scores
bModel adjusted for age, urbanization level, monthly income, and CCI scores
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survival rate of type 2 diabetes patients with HTN [44].
Moreover, the components of Jia-Wei-Xiao-Yao-San can
inhibit abnormal tau phosphorylation, suppress the release
of Aβ peptides, and decrease beta-amyloid-induced neuro-
toxicity [45, 46].
Another TCM herb, Jue-Ming-Zi (Semen Cassiae) has
shown neuroprotective effects in animal models of ische-
mic stroke and Parkinson’s disease [47]. Results of a recent
study also demonstrated that this herb can ameliorate
amyloid-β-induced synaptic dysfunction through anti-
inflammatory and Akt/GSK-3β pathways [48]. In our
study, all of the previously mentioned TCM agents re-
lieved the symptoms of HTN and decreased the risk of
developing dementia.
Although our study is the first to recently investigate
the effect of use of TCM on the risk of dementia among
subjects with HTN, there are some important limitations
to consider. First, identification of use of TCM and out-
comes were based on three categories in the ICD-9-CM,
and inaccurate diagnosis may have occurred. To minimize
this error, we only selected subjects with either HTN or
dementia after they were recorded as having at least three
outpatient visits reporting consistent diagnoses or one in-
patient admission for HTN. It should also be noted that
the NHI of Taiwan randomly samples claims from hospi-
tals, interviews patients, and reviews medical charts to
verify the accuracy of medical records. Second, we could
not account for other confounding factors, such as the use
of tobacco and alcohol, physical activity, dietary prefer-
ences, social network relationships, coping strategies, or
educational level, which were unavailable from the claims
data. Further studies controlling for those untested factors
are recommended to assess whether the present findings
are replicable among other demographically and geo-
graphically diverse groups. Third, we were unable to con-
tact the enrolled patients directly about the use of Chinese
herbs due to the anonymity of identification numbers in
the database. Even so, we were still able to demonstrate
the benefit from TCM use. Nearly 95% of dosing frequen-
cies in Chinese herbs are typically only used for one week
in clinical practice, so those who continued to receive the
same prescriptions for a longer period were therefore
likely to have used the prescribed medication [49]. Fourth,
the NHI program only pays for TCMs prescribed by
Chinese medicine physicians, not over-the-counter TCMs.
Therefore, the use of TCM may be underestimated. How-
ever, the NHI covers TCM prescriptions (the concentrated
herbal powder) manufactured by GMP-certified pharma-
ceutical companies in Taiwan. Within the NHI program,
the copayment for visiting a TCM clinic is only approxi-
mately 10 USD, which may greatly enhance the accessibil-
ity to TCM services. Fifth, findings from any retrospective
cohort study are generally less sound than these from
randomized trials because cohort study designs are subject
to various biases related to uncontrolled confounding
effects. Despite our careful attention to the study design,
employing adequate control of confounding factors, un-
predictable biases could still remain if they stem from
unmeasured or unknown confounders. Notwithstanding
these limitations, the strengths of this study must also be
acknowledged and these included the immediate availabil-
ity of data, the comprehensiveness of the database, and
the statistical power derived from the samples’ large
sizes. In addition, this retrospective 15-year cohort
study allowed us to examine in detail the association
of TCM usage with the subsequent risk of dementia,
and the corresponding findings could serve as a refer-
ence for future treatments.
Conclusions
The results of this population-based, retrospective co-
hort study show that the use of TCM during treatment
of HTN was associated with a 24% lower risk of devel-
oping dementia compared to the risk among non-TCM
users. TCM users had a significantly reduced risk of
Table 5 Risk of dementia in relation to the top 15 commonly
used TCMs




Tian-Ma-Gou-Teng-Yin a,c,d,e,f,g,h,i 0.77 (0.68–0.86) 0.82 (0.76–0.95)k
Dan-Shen a,d,e,f,g,h,i 0.71 (0.61–0.83) 0.80 (0.69–0.92)k
Gou-Teng-San 0.78 (0.65–0.92) 0.90 (0.74–1.07)
Gou-Teng 0.75 (0.61–0.90) 0.89 (0.75–1.08)
Xia-Ku-Cao 0.70 (0.56–0.86) 0.79 (0.60–1.02)
Zhi-Bai-Di-Huang-Wan 0.88 (0.68–1.10) 0.97 (0.76–1.23)
Da-Huang 0.89 (0.67–1.15) 0.92 (0.70–1.20)
Xue-Fu-Zhu-Yu-Tang 0.82 (0.67–0.99) 0.91 (0.75–1.21)
Chuan-Niu-Xi e,f,i 0.73 (0.58–0.92) 0.79 (0.62–0.98)k
Ge-Gen a,b,f,g,h,i 0.62 (0.43–0.79) 0.65 (0.52–0.83)k
Qi-Ju-Di-Huang-Wan 0.87 (0.68–1.12) 0.85 (0.66–1.09)
San-Qi 0.85 (0.66–1.10) 0.89 (0.69–1.19)
Tian-Ma 0.98 (0.79–1.22) 0.96 (0.77–1.19)
Jia-Wei-Xiao-Yao-San a,b,i 0.70 (0.54–0.91) 0.79 (0.64–0.98)k
Jue-Ming-Zi a,e,h,i 0.57 (0.41–0.80) 0.68 (0.49–0.96)k
HR hazard ratio, CI confidence interval
Potential therapeutic effects of the most promising TCMs:
aReduces β-amyloid protein or its toxicity







iMedicinal benefits in vascular risk factors
jModel adjusted for age, gender, urbanization level, monthly income, and
CCI scores
kPromising TCMs that were significantly related to the lower risk of dementia
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dementia compared to non-TCM users (adjusted
HR = 0.76; 95% CI = 0.74–0.81). The predominant effect
was observed among those treated with TCM longer than
180 days (adjusted HR = 0.65; 95% CI = 0.62–0.69). These
findings could serve as a reference for healthcare pro-
viders, in helping to establish more effective therapeutic
interventions to improve the prognosis of patients with
HTN and prevent subsequent dementia.
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